^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:Mektovi (binimetinib) (MEK inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    EADO-WCM 2021
    Title:

    Preclinical evaluation of Braftovi (encorafenib) plus Mektovi (binimetinib) in NRAS mutated patient-derived xenografts (PDXs)

    Published date:
    04/15/2021
    Excerpt:
    NRAS-mutant melanoma cells, as well as tissue slice cultures of patient tumors are treated with BRAF and MEK inhibitors alone and in combination....In vivo the combination therapy of encorafenib with binimetinib resulted in significantly reduced tumor growth compared to the control and encorafenib groups...